Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland

Doan QV, Gillard P, Brashear A, Halperin M, Hayward E, Varon S, Lu ZJ

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1111/ene.12062

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Botulinum Toxins, Type A /economics /therapeutic use; Clinical Trials as Topic /economics; Cost of Illness; Cost-Benefit Analysis /economics; Female; Hand; Health Care Costs; Health Services /utilization; Humans; Male; Models, Economic; Muscle Spasticity /complications /drug therapy /economics; Neurotoxins /economics /therapeutic use; Quality-Adjusted Life Years; Scotland; Stroke /complications /drug therapy /economics /mortality; Upper Extremity; Wrist

AccessionNumber
22013018556

Date bibliographic record published
13/06/2013